CXCL13 and neoplasm: The expressions of serum CXCL13, ICAM-1, MCP-5, IL-7, and TNF-α in tumor-bearing mice treated with rAd-mIL-28B were lower compared to rAd-EGFP-treated mice (P < 0.05) (Figure 4(c)).